Debra L. Richardson, MD, FACS, FACOG

home / authors / debra-l-richardson-md-facs-facog

Articles

Debra L. Richardson, MD, FACS, FACOG

Dr Richardson on the Safety of Upifitamab Rilsodotin in Platinum-Resistant Ovarian Cancer

Debra L. Richardson, MD, FACS, FACOG
April 9th 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.

Read More

Debra L. Richardson, MD, FACS, FACOG

Dr Richardson on the UPLIFT Trial of Upifitamab Rilsodotin in Ovarian Cancer

Debra L. Richardson, MD, FACS, FACOG
April 8th 2024

Debra L. Richardson, MD, FACS, FACOG, discusses outcomes seen with upifitamab rilsodotin in the phase 1/2 UPLIFT trial for patients with ovarian cancer.

Read More

Debra L. Richardson, MD, FACS, FACOG

Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

Debra L. Richardson, MD, FACS, FACOG
January 3rd 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Read More

Debra L. Richardson, MD, FACS, FACOG

Dr. Richardson on the Rationale for the UPNEXT Trial in Ovarian Cancer

Debra L. Richardson, MD, FACS, FACOG
February 2nd 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data